CORE COMPONENT G: ADMINISTRATION The administrative core supports all administrative and budgetary aspects of the Program Project. These support services include: 1. Clinical Coordinator Team - a group of physicians and a clinical specialist who are responsible for the initial contact with referring physicians and patients, patient financial counseling, scheduling and protocol assignments. 2. Protocol Management Team - a group of individuals responsible for coordinating protocol development, review, renewal and monitoring. 3. Grant Coordinator - the individual responsible for financial management of this Program Project grant. 4. Research Nurse Facilitator- a research nurse specialist responsible for facilitating the initiation and conduct of clinical trials. 5. Word Processing andAdministrative Services - a group of individuals responsible for word-processing manuscripts and submitting manuscripts for publication; updating citation and grant databases; creating presentation materials for internal investigator meetings and external scientific conferences; scheduling lectures, visitors and conferences. Relevance to Public Health: By providing essential administrative support, this core assists all projects on this grant in achieving the goal of making allogeneic hematopoietic cell transplantation safer, more effective, increasingly available, and applied more appropriately in the course of disease so as to maximize benefit and minimize risk.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018029-33
Application #
7617980
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2008-03-01
Budget End
2009-02-28
Support Year
33
Fiscal Year
2008
Total Cost
$799,844
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313

Showing the most recent 10 out of 1845 publications